By 2026, the integration of Artificial Intelligence (AI) and "Digital Twin" technology has begun to revolutionize biopsy planning. AI algorithms now analyze pre-procedure mammograms and MRIs to suggest the optimal entry point and needle trajectory, accounting for the unique vascularity and density of the patient's breast.
Some leading North American centers utilize a "Digital Twin" model—a biology-based mathematical simulation of the patient's breast tissue. This allows surgeons and radiologists to "practice" the biopsy virtually before the patient even enters the room. This personalized approach minimizes the time the patient spends under compression (in stereotactic cases) and ensures that the highest-risk portion of a heterogeneous mass is sampled on the first attempt.